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population. It is estimated that by the year 2030, this number will likely increase to 170Jo.
1 Respiratory infections are the fourth leading cause of death in the elderly, exceeded only by atherosclerosis, chronic obstructive pulmonary disease and cirrhosis of the liver. The greatly increased mortality of respiratory infections in the elderly has been ascribed to agerelated impairment in host defenses, 2-4 existing comorbid conditions like diabetes and atherosclerosis, increased oropharyngeal colonization with Gramnegative bacilli' and, finally, atypical presentations causing a delay in diagnosis.
Elderly patients undergo gradual physiological changes which influence absorption, distribution and elimination of certain drugs. Decreased lean body mass, total body water and albumin, as well as in-JIMA: Volume 24, 1992 -Page 11 DOI: http://dx.doi.org/10.5915/24-1-15451 creased body fat result in altered distribution of both lipophilic and hydrophilic agents. 6 • 7 In addition, hepatic and renal mechanisms of drug elimination gradually become less effective with advancing age. 6 • 1 While many new antimicrobial agents continue to be introduced for lower respiratory tract infections, their narrow margin of safety and limited spectrum of activity limit their use in the elderly.
When the sulfonamides first appeared in the 1930s, antimicrobial chemotherapy became a new clinical science. The sulfonamides seemed to represent an astounding therapeutic advance, but equally amazing improvements have appeared every decade since then. ln the 1940s, the miracle was penicillin G; in the 1950s, erythromycin, the tetracyclines, and chloramphenicol were the miracle drugs.
In the 1960s came ampicillin and methicillin, soon joined by the aminoglycosides and cephalosporins; thus, it became easier but infinitely more complex to care for patients with bacterial infections. Up to that time, practically any interested clinician could become an expert in managing infectious diseases. However, the need for specialists' help in this area became obvious to all in the 1960s.
In the 1970s, new penicillins and new cephalosporins began to appear regularly. In the 1980s, we saw improved cephalosporins and, more important, the newer fluoroquinolones, which are unique and represent an exciting development of the entire progression of antibiotics. ' The fluoroquinolones are active against the majority of aerobic Gram-positive and Gram-negative bacteria seen in clinical practice which are otherwise resistant to oral agents, i.e. Pseudomonas aeruqinosa. Clinical studies have shown that quinolones are effective in the treatment of infections of urinary tract, lower respiratory tract, skin and skin structures, bones and joints and gastrointestinal tract. Many of these infections that are treated successfully by ciprofloxacin are caused by pathogens that are resistant to other oral and parenteral antimicrobial agents. ' The data for this study was derived from a study conducted from January 1987 to June 1989 at Nassau County Medical Center, a 615-bed teriary care public hospital located in the suburbs of New York City. A total of 39 patients were considered evaluable for the study. One hundred forty patients were evaluated in a prospective clinical trial1 comparing sequential intravenous-oral administration of ciprofloxacin to intravenous ceftazidime in serious bacterial pneumonfas. Of the 144 patients evaluated in this study 39 patients were over 65 years of age and enrolled in our study. community-acquired, hospital-acquired, or nursing home-acquired bacterial pneumonia were enrolled in the study. All enrolled patients were over 65 years of age, range 65-94 years (mean age 79.1 years). Bacterial lower respiratory tract infection was diagnosed if patients had compatible clinical picture, i.e., fever over 37 .2 °C, total white blood cell count over 10,000/cu mm, and productive cough with purulent sputum, or a positive sputum culture from a specimen which, on Gram stain, had less tllan 25 squamous epithelial cells,and 25 or more neutrophils per low-power field. Patients were excluded if they were under 65 years of age, serum creatinine value was more than 2 mg/dl, allergic to quinolones, or if their condition was hemodynamically unstable.
Antibiotic administraction
Patients received sequential ciprofloxacin IV 200 mg Q 12 hours (mean 4.1 days), followed by 500 mg PO Q 12 hours (mean 5.8 days). Thirty-nine patients were enrolled in this group. Written, informed consent was granted by the patient or his/her legal guardian prior to enrollment.
Response definitions at the end of treatment were determined using the following definitions: 1) Complete resolution: disappearance of all signs and symptoms related to the infection. 2) Improvement: marked to moderate reduction in the severity and/or number of signs and symptoms of infection. 3) Failure: insufficient lessening of the signs and symptoms of infeciton to qualify as improvement.
Bacteriologic response was . determined using the following definitions: 1) Eradication: causative organism(2) absent at the end of treatment. 2) Persistence: causative organism present at the end of treatment judged to be causing a new infections process. 3) Indeterminate: bacteriologic response to study medication not evaluable for any reason, e.g., another anti-microbial with a similar spectrum of activity was administered before obtaining samples for the post-treatment cultures.
Clinical Monitoring
In addition to a baseline thorough history and physical, laboratory tests, including complete blood cell count and serum chemistry were performed before and after therapy. Pre-enrollment and followup chest roentgenography was performed in all patients. All patients were monitored daily for any adverse reactions in addition to daily documentation of physical examination, fever, cough and sputum production. Antibiotic therapy was evaluated using the following definitions: 
Results
During an 18-month period, between January 1988 and July 1989, 39 cases of pneumonia in patients over 65 years of age admitted to Nassau County Medical Center were evaluated.
Infection was classified as mild, moderate, or severe based on physical examination and radiographic signs. Cure was seen in 71 % of patients, regardless of severity of illness and existence of other comorbid conditions. Antibiotic failure was noted in one patient. One patient showed clinical deterioration and was changed to other antibiotics. Sputum showed Enterobacter aerogenes and Pseudomonas aeruginosa.
Adverse drug reaction was noted in only one patient. One patient in the ciprofloxacin group developed rash, fever while receiving rv ciprofloxacin, and this was discontinued.
In terms of mean number of days requiring hospitalization, IV ciprofloxacin was given for a mean of 4.1 days. Nonetheless, a majority of the patients could be discharged early in each group and followed up with oral ciprofloxacin.
Discussion
The proportion of patients in the United States who are over 65 years of age bas increased from 40/o to 12% in the last 80 years. The 12% of Americans over 65 years of age accounts for 40% of days in hospital, 25% of all medications used, and 33% of 11 New antimicrobials have been limited by their narrow margin of safety and limited spectrum of activity for their use in the elderly. In contrast, the newer quinolones, offer a number of advantages. • f) Of the 39 patients evaluated, five patients died in the hospital. This mortality figure of 130/o is low as compared to a mortality figure of 40% in other studies. u The mean age of our patients was 79. l years, and they had multiple medical problems that are associated with an increased risk of death . 1 i The low incidence of bacteremia, 2.5% may be related to a lower mortality rate, as pointed out in several studies. In the Marrie et al. study, .. 4% incidence of bacteremia was related to 40.5% mortality.
The presenting signs and symptoms in our patients, are similar to those represented by other investigtors." Sputum Gram stains and cultures are helpful in guiding therapy; obtaining adequate samples in the debilitated population is not easy. The isolation of Gram-negative bacteria, on sputum culture, corroborates with current literature. However, Staph. aureus,which is an uncommon isolate in sputum, was present in five patients. Streptococcus pneumonia isolated in five patients showed 100% cure rate. These findings are in keeping with the literature, where ciprofloxacin showed MIC's in the range of .85-3.4 g/ml, but resulted in 100% eradication.
•s-1 7 An explnation for this relates to the fact that ciprofloxacin has a high volume of distribution, suggestion that the drug 's concentration in tissues can well exceed serum levels for prolonged periods of time. "• 20 Bergogne et al. in a study of 21 patients, showed the ratio of serum to bronchial levels was .19 mg/ml at two hours and .95 mg/ml at six hours. 20 We believe that this unique pharmacokinetic feature of ciprofloxacin, whereby high concentrations of the drug are achieved and maintained in the bronchial and pulmonary parenchymal tissue, overcomes the marginal in vitro susceptibility against S. pneumoniae and helps explain the very high cure rate in this type of infection.
The patients enrolled in our study had multiple comorbid medical conditions. Out of 39 patients, three patients had tracheostomies. Ciprofloxacin is a suitable alternative to conventional antibiotics due to broad spectrum and availability of sequential intravenous and oral forms, which can result in reduced length of hospital stay. The concurrent presence of UTI and skin and bone infections, which are not uncommon in this age group, clearly make even long-term use of quinolones easy and cost effective. Ciprofloxacin has been shown to be safe and effective in the treatment of lower respiratory tract infections, particularly those caused by Gram-negative bacilli, including H. influenzae, Moraxella (Branchamella) catarrhalls Enterobacteriacae and P. aeruginosa. 21 Ciprofloxacin was effective in the treatment of pneumonia in the elderly, and the results were comparable to conventional parenteral antibiotic therapy. The drug was well tolerated and was cost effective. Thus, the fluoroquinolones represent an important new addition to the broad class of antimicrobials.
